AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34120135 — intervention group
Group type: COMPARATOR
Intervention: In-person simulation
Number of subjects: 115
Study 34120135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HMD and in-person)
Number of subjects: 115
Study 33181508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoperfusion (HP) with CytoSorb cartridge, 2 consecutive sessions started 6-7 days after hospital admission.
Number of subjects: 9
Study 33181508 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) without HP treatment.
Number of subjects: 9
Study 33181508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoperfusion (HP) with CytoSorb cartridge.
Number of subjects: 9
Study 34389273 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib plus R-B (Rituximab plus Bendamustine)
Number of subjects: 21
Study 34389273 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib plus R-CHOP (Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
Number of subjects: 21
Study 36065528 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment regimen (specific medications not detailed)
Number of subjects: 520
Study 36065528 — intervention group
Group type: COMPARATOR
Intervention: Continued observation
Number of subjects: 520
Study 36065528 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for infertility (specific medications not detailed)
Number of subjects: 520
Study 33995776 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 30
Study 33995776 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 30
Study 33995776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 33072497 — intervention group
Group type: EXPERIMENTAL
Intervention: Test results access (parent only vs. parent and clinic) and follow up approaches (yes/no)
Number of subjects: 240
Study 33072497 — intervention group
Group type: EXPERIMENTAL
Intervention: Kit distribution by clinicians
Number of subjects: 240
Study 35441466 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin produced by Bioton S.A. (0.3 units/kg)
Number of subjects: 56
Study 35441466 — intervention group
Group type: COMPARATOR
Intervention: Humulin® R (0.3 units/kg)
Number of subjects: 56
Study 33040565 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (40 Gy/15 fractions) with concurrent and adjuvant temozolomide (TMZ)
Number of subjects: 0
Study 33040565 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 0
Study 33040565 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (60 Gy/30 fractions)
Number of subjects: 0
Study 33040565 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 35947375 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid group (126 patients)
Number of subjects: 235
Study 35947375 — intervention group
Group type: COMPARATOR
Intervention: Control group (109 patients)
Number of subjects: 235
Study 32997647 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning strategy
Number of subjects: 33
Study 35789270 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab-based therapy
Number of subjects: 180
Study 35789270 — intervention group
Group type: COMPARATOR
Intervention: lapatinib-based therapy
Number of subjects: 180
Study 35789270 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab-lapatinib-based therapy
Number of subjects: 180
Study 35789270 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab-based neoadjuvant therapy in NeoSphere cohort
Number of subjects: 180
Study 35789270 — intervention group
Group type: EXPERIMENTAL
Intervention: whole study cohort in NeoSphere
Number of subjects: 180
Study 34090625 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 2040
Study 34090625 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 2040
Study 34090625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2040
Study 32141766 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan flufenamide + dexamethasone
Number of subjects: 0
Study 32141766 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide + dexamethasone
Number of subjects: 0
Study 33070223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mM l-carnitine
Number of subjects: 38
Study 33070223 — intervention group
Group type: COMPARATOR
Intervention: Control group (without l-carnitine)
Number of subjects: 38
Study 34118388 — intervention group
Group type: EXPERIMENTAL
Intervention: Browsing TikTok for 20 min
Number of subjects: 80
Study 34118388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TikTok browsing)
Number of subjects: 80
Study 34459765 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic therapy + inhalations with high concentrated oxygen with Camomile Oil
Number of subjects: 70
Study 34459765 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 70
Study 32115879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG) 3 mg
Number of subjects: 75
Study 32115879 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular glucagon (IMG) 1 mg
Number of subjects: 75
Study 34724145 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation set (Cox proportional hazards regression model)
Number of subjects: 2051
Study 34724145 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set (Cox proportional hazards regression model)
Number of subjects: 2051
Study 34724145 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation set (scoring model)
Number of subjects: 2051
Study 34724145 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set (scoring model)
Number of subjects: 2051
Study 33895720 — intervention group
Group type: EXPERIMENTAL
Intervention: Entry into differentiated service delivery (DSD) at 6 months after one suppressed viral load
Number of subjects: 90
Study 33895720 — intervention group
Group type: EXPERIMENTAL
Intervention: Entry into differentiated service delivery (DSD) at 6 months after two suppressed viral loads
Number of subjects: 90
Study 33895720 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (entry into DSD at 12 months after two suppressed viral loads)
Number of subjects: 90
Study 36322218 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based HIV/STI intervention
Number of subjects: 230
Study 36322218 — intervention group
Group type: COMPARATOR
Intervention: Control group (couples without IPV)
Number of subjects: 230
Study 33656475 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAM intervention (1 session/week during 4 weeks)
Number of subjects: 25
Study 33656475 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 25
Study 32943769 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (GI 32)
Number of subjects: 55
Study 32943769 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (GI 65)
Number of subjects: 55
Study 32943769 — intervention group
Group type: COMPARATOR
Intervention: Sucralose (non-caloric negative control)
Number of subjects: 55
Study 35831932 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and azathioprine (n=43)
Number of subjects: 85
Study 35831932 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=42)
Number of subjects: 85
Study 35831932 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (immunosuppressive therapy)
Number of subjects: 85
Study 35831932 — intervention group
Group type: COMPARATOR
Intervention: Group B (untreated control cohort)
Number of subjects: 85
Study 34196378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nox-T3 automatic scoring algorithm
Number of subjects: 283
Study 35115209 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum GDF-15 levels in patients with diabetes
Number of subjects: 3001
Study 35115209 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of serum GDF-15 to conventional risk factors in patients with diabetes
Number of subjects: 3001
Study 35115209 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 3001
Study 33766759 — intervention group
Group type: EXPERIMENTAL
Intervention: Soshiho-tang (SSHT) administered three times a day for 4 weeks
Number of subjects: 60
Study 33766759 — intervention group
Group type: EXPERIMENTAL
Intervention: Soshiho-tang (SSHT)
Number of subjects: 60
Study 33766759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35060622 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fixed-effects model (FE)
Number of subjects: 303
Study 35060622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic panel model using structural equation modeling (ML-SEM)
Number of subjects: 303
Study 34473068 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-enabled Integrated Care (IC) model
Number of subjects: 59
Study 34473068 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 59
Study 32998471 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus reuteri DSM 17938)
Number of subjects: 37
Study 32998471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (agave inulin)
Number of subjects: 37
Study 32998471 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Lactobacillus reuteri DSM 17938 plus agave inulin)
Number of subjects: 37
Study 32998471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 34153324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIC)
Number of subjects: 16
Study 34153324 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MICC)
Number of subjects: 16
Study 34153324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIR)
Number of subjects: 16
Study 34153324 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICR)
Number of subjects: 16
Study 35144203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics laboratory program (8 weeks, interactive education methods including ethical scenarios, case studies, roleplay, group discussions, project papers, and watching movies)
Number of subjects: 100
Study 35144203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics laboratory program (8 weeks, interactive education methods)
Number of subjects: 100
Study 35144203 — intervention group
Group type: COMPARATOR
Intervention: Standard fundamentals of nursing curriculum (control group)
Number of subjects: 100
Study 33818600 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-kHz spinal cord stimulation (SCS) plus conventional medical management (CMM)
Number of subjects: 216
Study 33818600 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 216
Study 33818600 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-kHz SCS plus CMM
Number of subjects: 216
Study 33818600 — intervention group
Group type: COMPARATOR
Intervention: CMM
Number of subjects: 216
Study 36315226 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioptron light therapy for 12 minutes three times per week plus standard wound care
Number of subjects: 40
Study 36315226 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care only
Number of subjects: 40
Study 32533228 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy plus cetuximab (arm A)
Number of subjects: 74
Study 32533228 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy (arm B)
Number of subjects: 74
Study 36240610 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of GH (SG), mean baseline GH dose of 0.13 mg/day increased to 0.31 mg/day at study end
Number of subjects: 18
Study 36240610 — intervention group
Group type: COMPARATOR
Intervention: Very low fixed dose of GH (LG), 0.1 mg/day
Number of subjects: 18
Study 36240610 — intervention group
Group type: COMPARATOR
Intervention: Very low fixed dose of GH (LG)
Number of subjects: 18
Study 34399063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined soy and hop extract (n=38)
Number of subjects: 78
Study 34399063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=40)
Number of subjects: 78
Study 616850292 — intervention group
Group type: EXPERIMENTAL
Intervention: Air powder abrasive system (AF)
Number of subjects: 9
Study 616850292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber cup with pumice powder (RC)
Number of subjects: 9
Study 616850292 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 9
Study 35137287 — intervention group
Group type: EXPERIMENTAL
Intervention: SG?+?RF
Number of subjects: 278
Study 35137287 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 278
Study 34120150 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 98
Study 34120150 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide 5 mg/day
Number of subjects: 98
Study 35763588 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCEL-2 group
Number of subjects: 25
Study 35763588 — intervention group
Group type: COMPARATOR
Intervention: ACCEL-1 group
Number of subjects: 25
Study 35763588 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 25
Study 34707496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejiao (6 g/day)
Number of subjects: 210
Study 34707496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 35373729 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mate extract
Number of subjects: 0
Study 35373729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32665197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless circumcision (Group 1)
Number of subjects: 182
Study 32665197 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures (Group 2)
Number of subjects: 182
Study 36106379 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (≤8 mg/day)
Number of subjects: 0
Study 36106379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32653580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task gait and balance training
Number of subjects: 20
Study 32653580 — intervention group
Group type: COMPARATOR
Intervention: Single-task gait and balance training
Number of subjects: 20
Study 34989808 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Disorder
Number of subjects: 163
Study 34989808 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal Sleep Disruption
Number of subjects: 163
Study 34989808 — intervention group
Group type: COMPARATOR
Intervention: Low Complaint
Number of subjects: 163
Study 33411545 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Reflection Resilience Training (SRT; n = 96)
Number of subjects: 204
Study 33411545 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 108)
Number of subjects: 204
Study 32775442 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern contraceptive methods
Number of subjects: 580
Study 32775442 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 35 years
Number of subjects: 580
Study 32775442 — intervention group
Group type: EXPERIMENTAL
Intervention: Able to read and write
Number of subjects: 580
Study 32775442 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary school education
Number of subjects: 580
Study 32775442 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary school education
Number of subjects: 580
Study 32775442 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseled on contraceptive methods
Number of subjects: 580
Study 32775442 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate knowledge on modern contraceptive method
Number of subjects: 580
Study 32775442 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge on modern contraceptive method
Number of subjects: 580
Study 35317611 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming iTBS
Number of subjects: 42
Study 35317611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpriming iTBS
Number of subjects: 42
Study 35317611 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study 35317611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror visual feedback
Number of subjects: 42
Study 32320172 — intervention group
Group type: EXPERIMENTAL
Intervention: ABA intervention (assets-based approach with behaviour change techniques)
Number of subjects: 103
Study 32320172 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data from women, infant-feeding helpers, and maternity services
Number of subjects: 103
Study 32320172 — intervention group
Group type: COMPARATOR
Intervention: N/A (usual care)
Number of subjects: 103
Study 33261505 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I particle‐integrated esophageal covered stent and hyperbaric oxygen
Number of subjects: 45
Study 33261505 — intervention group
Group type: COMPARATOR
Intervention: 125I particle‐integrated esophageal covered stent
Number of subjects: 45
Study 35575780 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS software
Number of subjects: 40
Study 35575780 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medication workflow)
Number of subjects: 40
Study 33847634 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) and methylene blue (MB) combination method
Number of subjects: 415
Study 33847634 — intervention group
Group type: COMPARATOR
Intervention: Methylene blue (MB) method alone
Number of subjects: 415
Study 34412906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictograms on prescription medication labels
Number of subjects: 250
Study 34412906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictograms for dose and route of administration, and dosage frequency
Number of subjects: 250
Study 34412906 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessed pictograms
Number of subjects: 250
Study 32499018 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation (CS)
Number of subjects: 120080
Study 32499018 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 120080
Study 35649964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle arthrodesis combined with mosaic bone autograft transplantation
Number of subjects: 20
Study 35649964 — intervention group
Group type: COMPARATOR
Intervention: Ankle arthrodesis (control group)
Number of subjects: 20
Study 34650034 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus carboplatin and pemetrexed administered every three weeks for up to six cycles, followed by maintenance of toripalimab and pemetrexed.
Number of subjects: 40
Study 34650034 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus chemotherapy (carboplatin and pemetrexed)
Number of subjects: 40
Study 34650034 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker analysis
Number of subjects: 40
Study 32135135 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes
Number of subjects: 2458
Study 32135135 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels at weeks 10-14
Number of subjects: 2458
Study 36328209 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD) after SEMS placement
Number of subjects: 44
Study 36328209 — intervention group
Group type: COMPARATOR
Intervention: Conventional biliary drainage alone (Control)
Number of subjects: 44
Study 36328209 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD)
Number of subjects: 44
Study 33569770 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment for 48 weeks
Number of subjects: 142
Study 33569770 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 142
Study 32713702 — intervention group
Group type: COMPARATOR
Intervention: Low Grass Hay (LGH) - 10% GH
Number of subjects: 45
Study 32713702 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Grass Hay (MGH) - 17.5% GH
Number of subjects: 45
Study 32713702 — intervention group
Group type: EXPERIMENTAL
Intervention: High Grass Hay (HGH) - 25% GH
Number of subjects: 45
Study 32713702 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (LGH, MGH, HGH)
Number of subjects: 45
Study 35446178 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 12
Study 32942949 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 15
Study 32367657 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) performed in 2018 (post-DAWN trial)
Number of subjects: 443
Study 32367657 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) in late presenters in 2018 (post-DAWN trial)
Number of subjects: 443
Study 32367657 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) sensitivity, specificity, and proportions of CTP with a final diagnosis of acute stroke, TIA or non-stroke
Number of subjects: 443
Study 32367657 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) utilization in 2018 (post-DAWN trial)
Number of subjects: 443
Study 35216560 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Medical Evaluation (IME)
Number of subjects: 5888
Study 35216560 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 5888
Study 35114159 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with chemotherapy
Number of subjects: 0
Study 35114159 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34257640 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 47
Study 34257640 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 47
Study 35332062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab + Niraparib (Part A)
Number of subjects: 55
Study 35332062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab + Carboplatin-Paclitaxel (Part B)
Number of subjects: 55
Study 35332062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab + Niraparib + Bevacizumab (Part C)
Number of subjects: 55
Study 35332062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab + Carboplatin-Paclitaxel + Bevacizumab (Part D)
Number of subjects: 55
Study 34810368 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax
Number of subjects: 30